For many people living with hemophilia, every day involves a careful balance of wanting to live fully, while also thinking through risks, bleeds, and the planning that comes with managing a chronic condition. That doesn’t always get talked about, but it’s real. And it’s why having options truly matters. Gene therapy is one of those options. For some, it may feel like a meaningful new possibility as they think about their future with hemophilia. Each person should have the chance to explore gene therapy on their own terms, with honest, evidence-based information and the support of people who know their story. People deserve clear information and coverage policies that reflect FDA labeled indications and current standards of care. That way decisions remain where they belong: with individuals and their clinicians. That’s why the National Bleeding Disorders Foundation 's statement on shared decision making and access is so important. It reinforces that health decisions belong with those who live with hemophilia, supported by their hematologist, their HTC team, and those who truly understand the lived realities behind every choice. People living with hemophilia deserve care that listens, respects their experience, and empowers them with options including innovative therapies like gene therapy. The NBDF’s statement is worth reading and sharing: https://bit.ly/4q8CjV9 #genetherapy #NBDF #hemophilia #bleedingdisorder
CSL's 2026 Half Year Financial Results
CSL will announce its Half Year Financial Results for the period ending 31st December 2025 on Wednesday, 11th February 2026.
Webcast will be live from 10:00am (AEDT) on announcement day.
Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report → | Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report → | CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
Rare Disease Day is February 28th. To shine a light on those battling rare diseases, today we’re highlighting hemophilia, a rare bleeding disorder that affects the blood's ability to clot. More: https://lnkd.in/gkfd4At3 #CSL #RareDiseaseDay #Hemophilia
Iron deficiency can quietly steal energy, focus, and quality of life. And yet, it’s often missed, dismissed, or misunderstood. At CSL, we’re working to change the story by raising awareness and delivering treatments to help people feel like themselves again. Click the link to learn more: www.csl.com/impact #CSL #CSLImpactReport #IronDeficiency
At CSL, every story matters, and we’re proud to share one of them. Watch this short video to see how working at CSL makes real-world impact: https://bit.ly/4sZLKZI Our teams bring science, care and purpose together to improve lives. Ready to join a community where purpose meets possibility? Visit https://bit.ly/3Z1unu4. #CSLCareers #PurposeDriven #LifeAtCSL #TeamCSL
Behind every award-winning facility are teams who bring innovation, collaboration and excellence to life. CSL’s plasma fractionation facility, recognized with the 2025 Pharmaceutical Engineering Award, reflects our commitment to a culture where engineering, science and purpose come together. Build a career shaped by excellence: https://bit.ly/45Z6KpF #CSLCareers #LifeAtCSL #EngineeringCareers #PromisingFutures #CSL
At #JPM2026 , CSL ’s new Global Head of Search & Evaluation, Stephen Pitt, PhD, joined Endpoints News News to spotlight the company’s century‑long record of advancing treatments for rare and serious diseases. From pioneering gene therapies in haemophilia B to delivering first‑in‑class options for hereditary angioedema, Stephen shared how CSL scales impact by partnering with the best and brightest innovators. Beyond our 100+ partnering meetings around Union Square, San Francisco this week, we’re busy connecting with biotech leaders and entrepreneurs across hematology, cardiovascular/renal, and immunology to co‑develop the next generation of breakthrough medicines. If you’re advancing new therapies with the potential to change patient lives, CSL would welcome a conversation. We’re a $55 billion global biotech that invests $1.4 billion annually in R&D to deliver therapies and vaccines to people in over 100 countries. Let’s shape the next century of innovation together! #CSL
What does life with chronic kidney disease really look like? It’s more than dialysis machines and doctor visits. It’s about resilience and holding onto dreams. Last fiscal year, CSL medicines treated 184,000 patients for conditions associated with #kidneydisease . Learn more about how CSL makes an impact on kidney care: www.csl.com/impact #CSL #CSLImpactReport #ChronicKidneyDisease
At CSL, we turn big ideas into reality. Protecting public health is in the DNA of who we are and our newest manufacturing site at Tullamarine, Melbourne reflects that mission back every day in a modern, efficient, and highly scalable way. Learn more about how this high-tech vaccine and antivenom manufacturing facility is helping meet needs in the Southern Hemisphere. https://bit.ly/4pNewdn #CSL #CSLSeqirus #Manufacturing #Tullamarine #Melbourne #Australia #Antivenom #Innovation
CSL is investing $1.5 billion to expand global plasma therapy capabilities, strengthening supply, accelerating innovation and meeting the growing needs of patients worldwide. It’s one of many ways our teams drive meaningful change in plasma science and manufacturing. Help shape the future of lifesaving therapies: https://bit.ly/4sCGn2C #CSLCareers #Innovation #Impact #LifeSciences #PlasmaScience #CSL
Join CSL's new VP and Head of Search & Evaluation Stephen Pitt, PhD, at Endpoints at #JPM26 this Monday. Attend live or virtually to hear how we’re partnering to fuel CSL's Second Century of Global Biotech Innovation. Find the full agenda and registration info here: https://bit.ly/49tYWgq
